The primary endpoint is the change from baseline in non-vellus target area hair count (TAHC) at the end of week 24. The drug will be dosed at 10 mg (0.5% BID) per patient per day in the trial.[4]
Adverse effects
Pyrilutamide is generally well-tolerated. The most common adverse event is contact dermatitis.[5]
Pharmacology
Plasma concentration of pyrilutamide and metabolite KX-982 in different dose groups in phase Ib clinical trials in China
Pharmacodynamics
Pyrilutamide binds to the androgen receptor with a very high affinity with an IC50 of 0.28 nM. [3] Reference drug bicalutamide had an IC50 of 3.1 nM. [3]
References
^Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R (January 2023). "What's New in Therapy for Male Androgenetic Alopecia?". American Journal of Clinical Dermatology. 24 (1): 15–24. doi:10.1007/s40257-022-00730-y. PMID36169916.